ABCC3 and lung cancer: In lung cancer, carboplatin is responsible for increasing the expression of MRP3,[23] and acquired paclitaxel resistance during carboplatin cotherapy often appears to be a function of MRP3.[21] Many cisplatin-treated cells also upregulate MRP3,[20] and platinum resistance is associated with MRP3 in lung cancer.[26, 27] The polymorphism identified in the present study (rs1051640; E1503E) has also been observed in relation to cisplatin-induced ototoxicity;[24, 25] however, no study has yet characterized the functional effects of E1503E to our knowledge.